Eugenia Domingo-Guell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Eugenia Domingo-Guell has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alba Fernandez-Bonet
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain
2 shared publications - Blanca Rodríguez‐Fernández
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain
2 shared publications - Gerard Temprano-Sagrera
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain
2 shared publications - Gonzalo Sánchez-Benavides
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain
2 shared publications - Jordi Huguet
Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain
2 shared publications Mariateresa Buongiorno
Neurology Department, Vall d’Hebron University Hospital, Barcelona, Spain
2 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
Multidomain determinants of perivascular spaces indicate early cerebrovascular vulnerability in individuals at risk of Alzheimer’s disease
Background: Perivascular spaces (PVS) are MRI-visible markers of cerebrovascular and glymphatic function, but their regional determinants in preclinical Alzheimer’s disease (AD), regarding sex and AD biomarkers, remain poorly understood. Methods: We studied 1199 cognitively unimpaired ALFA study participants (aged 54–65 years), genetically enriched for AD risk, with CSF biomarker phenotyping in 296 participants. PVS were automatically quantified in basal ganglia, centrum semiovale, hippocampus, and midbrain on 3T MRI. Counts were modeled using Poisson or negative binomial regression, adjusting for demographics, cardiometabolic, lifestyle, and genetic factors, with effect modification by sex and amyloid/tau (AT) status. Results: PVS showed marked regional specificity. Centrum semiovale PVS were associated with age, male sex, and cardiometabolic factors, whereas hippocampal and midbrain PVS were more closely related to AD biomarker status and sleep or psychological measures. Men exhibited higher centrum semiovale burden while women showed higher counts in hippocampus, midbrain, and basal ganglia. Associations were stronger in amyloid-positive individuals with concurrent tau pathology. Polygenic scores for lipid and metabolic traits contributed modestly to regional PVS variation. Conclusions: PVS burden is associated with multidomain determinants in preclinical AD with regional, sex-specific, and biomarker-dependent patterns, supporting PVS as accessible MRI markers for risk stratification and precision prevention. “Early Identification of Markers in Alzheimer’s Families/ALFA (ALFA Cohort)” ( https://clinicaltrials.gov/study/NCT02485730 ). Registration number: NCT02485730.
- 28 October 2026
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
Open AccessMultidomain determinants of perivascular spaces indicate early cerebrovascular vulnerability in individuals at risk of Alzheimer’s disease
Background: Perivascular spaces (PVS) are MRI-visible markers of cerebrovascular and glymphatic function, but their regional determinants in preclinical Alzheimer’s disease (AD), regarding sex and AD biomarkers, remain poorly understood. Methods: We studied 1199 cognitively unimpaired ALFA study participants (aged 54–65 years), genetically enriched for AD risk, with CSF biomarker phenotyping in 296 participants. PVS were automatically quantified in basal ganglia, centrum semiovale, hippocampus, and midbrain on 3T MRI. Counts were modeled using Poisson or negative binomial regression, adjusting for demographics, cardiometabolic, lifestyle, and genetic factors, with effect modification by sex and amyloid/tau (AT) status. Results: PVS showed marked regional specificity. Centrum semiovale PVS were associated with age, male sex, and cardiometabolic factors, whereas hippocampal and midbrain PVS were more closely related to AD biomarker status and sleep or psychological measures. Men exhibited higher centrum semiovale burden while women showed higher counts in hippocampus, midbrain, and basal ganglia. Associations were stronger in amyloid-positive individuals with concurrent tau pathology. Polygenic scores for lipid and metabolic traits contributed modestly to regional PVS variation. Conclusions: PVS burden is associated with multidomain determinants in preclinical AD with regional, sex-specific, and biomarker-dependent patterns, supporting PVS as accessible MRI markers for risk stratification and precision prevention. “Early Identification of Markers in Alzheimer’s Families/ALFA (ALFA Cohort)” ( https://clinicaltrials.gov/study/NCT02485730 ). Registration number: NCT02485730.
- Open Access
Multidomain determinants of perivascular spaces indicate early cerebrovascular vulnerability in individuals at risk of Alzheimer’s disease
Background: Perivascular spaces (PVS) are increasingly recognized as MRI-visible markers of cerebrovascular and glymphatic functions. However, the determinants of regional PVS burden in the preclinical stages of Alzheimer’s disease (AD) remain to be elucidated, particularly when considering the impact of sex and core AD biomarkers. Methods: We studied 1,199 cognitively unimpaired participants from the ALFA cohort, enriched for AD genetic risk and deeply phenotyped, including cerebrospinal fluid (CSF) biomarkers. PVS were automatically quantified in the basal ganglia, centrum semiovale, hippocampus, and midbrain on 3T MRI. Regional PVS counts were modeled using Poisson or negative binomial regression, accounting for demographics, cardiometabolic, lifestyle and genetic factors. Effect modification by sex and CSF amyloid/tau (AT) classification was examined. Results: Determinants of PVS burden showed marked regional specificity. In the centrum semiovale, PVS burden was associated with age, male-sex and cardiometabolic factors. In contrast, hippocampal and midbrain PVS were more closely related to AD biomarker status and to psychological or sleep-related measures. Pronounced sex differences were observed, with men exhibiting higher PVS burden in centrum semiovale, while women showed higher PVS counts in the hippocampus, midbrain and basal ganglia. Associations between vascular, lifestyle, and genetic factors and PVS burden were stronger in amyloid-positive individuals, particularly those with concurrent amyloid and tau pathology, suggesting increased perivascular vulnerability along the AD continuum. Genetic risk scores for metabolic and lipid-related traits contributed modestly and independently to regional PVS variation, with evidence of sex- and biomarker-specific effects. Conclusions: PVS burden reflects multidomain influences on cerebrovascular and clearance dysfunction in preclinical AD, with distinct regional, sex-specific, and biomarker-dependent patterns. These findings support PVS as an accessible MRI marker of early cerebrovascular vulnerability and highlight their potential relevance for risk stratification and precision prevention strategies before symptom onset.
Open AccessMultidomain determinants of perivascular spaces indicate early cerebrovascular vulnerability in individuals at risk of Alzheimer’s disease
Background: Perivascular spaces (PVS) are increasingly recognized as MRI-visible markers of cerebrovascular and glymphatic functions. However, the determinants of regional PVS burden in the preclinical stages of Alzheimer’s disease (AD) remain to be elucidated, particularly when considering the impact of sex and core AD biomarkers. Methods: We studied 1,199 cognitively unimpaired participants from the ALFA cohort, enriched for AD genetic risk and deeply phenotyped, including cerebrospinal fluid (CSF) biomarkers. PVS were automatically quantified in the basal ganglia, centrum semiovale, hippocampus, and midbrain on 3T MRI. Regional PVS counts were modeled using Poisson or negative binomial regression, accounting for demographics, cardiometabolic, lifestyle and genetic factors. Effect modification by sex and CSF amyloid/tau (AT) classification was examined. Results: Determinants of PVS burden showed marked regional specificity. In the centrum semiovale, PVS burden was associated with age, male-sex and cardiometabolic factors. In contrast, hippocampal and midbrain PVS were more closely related to AD biomarker status and to psychological or sleep-related measures. Pronounced sex differences were observed, with men exhibiting higher PVS burden in centrum semiovale, while women showed higher PVS counts in the hippocampus, midbrain and basal ganglia. Associations between vascular, lifestyle, and genetic factors and PVS burden were stronger in amyloid-positive individuals, particularly those with concurrent amyloid and tau pathology, suggesting increased perivascular vulnerability along the AD continuum. Genetic risk scores for metabolic and lipid-related traits contributed modestly and independently to regional PVS variation, with evidence of sex- and biomarker-specific effects. Conclusions: PVS burden reflects multidomain influences on cerebrovascular and clearance dysfunction in preclinical AD, with distinct regional, sex-specific, and biomarker-dependent patterns. These findings support PVS as an accessible MRI marker of early cerebrovascular vulnerability and highlight their potential relevance for risk stratification and precision prevention strategies before symptom onset.